Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
sector : N::A symbols : Tevjf save search
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
Published: 2024-04-19 (Crawled : 10:00) - globenewswire.com
ALVO | News | $13.23 2.64% 2.57% 1.7M
|
n/a
|
| O: 1.16%
H: 7.28%
C: 1.3%
KMDA | News | $5.05 -0.98% -0.99% 27K
|
Health Technology
|
| O: 1.76%
H: 0.0%
C: 0.0%
humira biosimilar approved for agreement
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
Published: 2024-04-16 (Crawled : 21:00) - globenewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.04%
H: 0.28%
C: -0.16%
stelara fda biosimilar approval teva
Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024
Published: 2024-04-03 (Crawled : 11:00) - globenewswire.com
ALVO | News | $13.23 2.64% 2.57% 1.7M
|
n/a
|
| O: 2.98%
H: 0.17%
C: -0.43%
KMDA | News | $5.05 -0.98% -0.99% 27K
|
Health Technology
|
| O: -0.18%
H: 2.16%
C: 0.9%
audio
Alvotech Announces Increase in Number of Own Shares
Published: 2024-03-22 (Crawled : 20:00) - globenewswire.com
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
KMDA | News | $5.05 -0.98% -0.99% 27K
|
Health Technology
| Email alert
Add to watchlist
ALVO | News | $13.23 2.64% 2.57% 1.7M
|
n/a
| Email alert
Add to watchlist
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
Published: 2024-03-20 (Crawled : 20:00) - globenewswire.com
ALVO | News | $13.23 2.64% 2.57% 1.7M
|
n/a
|
| O: -1.58%
H: 1.87%
C: 0.53%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.03%
H: 0.0%
C: 0.0%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.89%
H: 0.0%
C: 0.0%
KMDA | News | $5.05 -0.98% -0.99% 27K
|
Health Technology
|
| O: 0.68%
H: 0.0%
C: -1.86%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.58%
H: 1.2%
C: 0.84%
business year update financial results
Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET
Published: 2024-03-05 (Crawled : 21:00) - globenewswire.com
ALVO | News | $13.23 2.64% 2.57% 1.7M
|
n/a
|
| O: -0.99%
H: 0.75%
C: -0.13%
KMDA | News | $5.05 -0.98% -0.99% 27K
|
Health Technology
|
| O: -6.12%
H: 1.67%
C: 1.17%
year financial results
Alvotech Appoints Interim Chief Quality Officer
Published: 2024-02-29 (Crawled : 21:00) - globenewswire.com
ALVO | News | $13.23 2.64% 2.57% 1.7M
|
n/a
|
| O: -0.58%
H: 3.04%
C: 3.01%
KMDA | News | $5.05 -0.98% -0.99% 27K
|
Health Technology
|
| O: -1.27%
H: 2.97%
C: 2.41%
Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share
Published: 2024-02-26 (Crawled : 10:00) - globenewswire.com
ALVO | News | $13.23 2.64% 2.57% 1.7M
|
n/a
|
| O: 11.35%
H: 0.84%
C: -3.25%
KMDA | News | $5.05 -0.98% -0.99% 27K
|
Health Technology
|
| O: 0.0%
H: 1.6%
C: -0.49%
million
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
Published: 2024-02-24 (Crawled : 04:20) - globenewswire.com
KMDA | News | $5.05 -0.98% -0.99% 27K
|
Health Technology
| Email alert
Add to watchlist
ALVO | News | $13.23 2.64% 2.57% 1.7M
|
n/a
| Email alert
Add to watchlist
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
simlandi first biosimilar approval teva
Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)
Published: 2024-02-15 (Crawled : 12:00) - globenewswire.com
ALVO | News | $13.23 2.64% 2.57% 1.7M
|
n/a
|
| O: 0.32%
H: 2.98%
C: 0.32%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.19%
H: 1.6%
C: 1.24%
KMDA | News | $5.05 -0.98% -0.99% 27K
|
Health Technology
|
| O: 1.66%
H: 1.96%
C: 0.49%
avt04 stelara biosimilar expected global market
Generic Drugs Market to grow by USD 176.25 billion from 2022 to 2027, North America is estimated to contribute 37% to the growth - Technavio
Published: 2024-02-08 (Crawled : 05:00) - prnewswire.com
ENDPQ | $0.0006 -50.0% 3.4K
|
n/a
|
| O: -14.29%
H: 16.67%
C: 0.0%
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: 0.82%
H: 0.0%
C: 0.0%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -1.64%
H: 0.0%
C: 0.0%
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: -0.34%
H: 0.0%
C: -1.2%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -1.57%
H: 0.26%
C: -0.47%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.48%
H: 0.16%
C: 0.0%
BAX | $39.47 -0.45% 0.0% 2.8M
|
Health Technology
|
| O: -0.96%
H: 5.91%
C: 3.74%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: -1.41%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -2.25%
H: 0.0%
C: 0.0%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.38%
H: 0.34%
C: -0.72%
america growth market
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
Published: 2024-01-29 (Crawled : 09:00) - globenewswire.com
ALVO | News | $13.23 2.64% 2.57% 1.7M
|
n/a
|
| O: 2.39%
H: 4.67%
C: 1.67%
KMDA | News | $5.05 -0.98% -0.99% 27K
|
Health Technology
|
| O: -1.05%
H: 0.41%
C: -0.35%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.11%
H: 0.7%
C: 0.65%
avt03 prolia biosimilar positive results study
Ibuprofen API Market Records Growth of USD 31.68 million from 2022 to 2027, Major Innovations and Key Vendor Offerings - Technavio
Published: 2024-01-23 (Crawled : 10:00) - prnewswire.com
MNKPF | $17.25
|
n/a
| Email alert
Add to watchlist
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
MNKKQ | $0.02
|
Manufacturing
| Email alert
Add to watchlist
MNKTQ | $0.12 -66.67% 39K
|
Manufacturing
| Email alert
Add to watchlist
MNK | $0.3402 -0.06% 540K
|
n/a
| Email alert
Add to watchlist
million key growth market
Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04
Published: 2024-01-19 (Crawled : 17:00) - globenewswire.com
ALVO | News | $13.23 2.64% 2.57% 1.7M
|
n/a
|
| O: 6.64%
H: 11.54%
C: 8.1%
KMDA | News | $5.05 -0.98% -0.99% 27K
|
Health Technology
|
| O: -0.85%
H: 1.46%
C: 0.69%
avt02 avt04 license update
Paracetamol Market to grow by USD 791.9 million from 2022 to 2027, North America accounts for 37% of market growth- Technavio
Published: 2024-01-17 (Crawled : 09:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: -0.56%
H: 0.0%
C: 0.0%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -1.83%
H: 0.0%
C: 0.0%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.08%
H: 0.1%
C: -0.18%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.45%
H: 0.06%
C: -0.5%
america million market
STADA and Alvotech Secure Approval for Uzpruvo, Europe’s First Ustekinumab Biosimilar to Stelara
Published: 2024-01-10 (Crawled : 09:00) - globenewswire.com
ALVO | News | $13.23 2.64% 2.57% 1.7M
|
n/a
|
| O: -0.72%
H: 1.77%
C: -1.53%
KMDA | News | $5.05 -0.98% -0.99% 27K
|
Health Technology
|
| O: -0.66%
H: 0.71%
C: 0.17%
first biosimilar approval stelara
Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea® (aflibercept)
Published: 2024-01-03 (Crawled : 09:00) - globenewswire.com
ALVO | News | $13.23 2.64% 2.57% 1.7M
|
n/a
|
| O: 1.23%
H: 2.17%
C: 1.57%
KMDA | News | $5.05 -0.98% -0.99% 27K
|
Health Technology
|
| O: -0.97%
H: 1.53%
C: 0.0%
avt06 eylea candidate biosimilar results study
Erectile Dysfunction (ED) Drugs Market to grow by USD 1.44 billion from 2023-2028, North America to account for 41% of market growth - Technavio
Published: 2023-12-14 (Crawled : 00:00) - prnewswire.com
ENDPQ | $0.0006 -50.0% 3.4K
|
n/a
|
| O: 0.0%
H: 110.0%
C: 10.0%
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: -0.87%
H: 1.07%
C: -0.29%
america growth market
Active Pharmaceutical Ingredients Market to Surpass $372.4 Billion, Globally, by 2030 at 6.8% CAGR: Coherent Market Insights (CMI)
Published: 2023-12-08 (Crawled : 15:00) - prnewswire.com
ENDPQ | $0.0006 -50.0% 3.4K
|
n/a
|
| O: -20.0%
H: 0.0%
C: 0.0%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -1.29%
H: 0.4%
C: 0.4%
PPCB | $0.001 -41.86% 11M
|
Manufacturing
|
| O: 0.0%
H: 2.61%
C: -4.35%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.07%
H: 1.1%
C: 0.45%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.19%
H: 0.35%
C: 0.2%
active market
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
Published: 2023-11-29 (Crawled : 09:00) - globenewswire.com
ALVO | News | $13.23 2.64% 2.57% 1.7M
|
n/a
|
| O: 1.02%
H: 0.0%
C: -5.05%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.04%
H: 0.0%
C: 0.0%
KMDA | News | $5.05 -0.98% -0.99% 27K
|
Health Technology
|
| O: 0.73%
H: 0.0%
C: -1.04%
avt05 simponi biosimilar positive results study
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.